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Abstract
Background Because of the vulnerability and frailty of
elderly adults, clinical drug development has traditionally
been biased towards young and middle-aged adults. Recent
efforts have begun to incorporate data from paediatric
investigations. Nevertheless, the elderly often remain
underrepresented in clinical trials, even though persons
aged 65 years and older receive the majority of drug pre-
scriptions. Consequently, a knowledge gap exists with
regard to pharmacokinetic (PK) and pharmacodynamic
(PD) responses in elderly subjects, leaving the safety and
efficacy of medicines for this population unclear.
Objectives The goal of this study was to extend a physi-
ologically based pharmacokinetic (PBPK) model for adults
to encompass the full course of healthy aging through to
the age of 100 years, to support dose selection and improve
pharmacotherapy for the elderly age group.
Methods For parameterization of the PBPK model for
healthy aging individuals, the literature was scanned for
anthropometric and physiological data, which were con-
solidated and incorporated into the PBPK software PK-
Sim. Age-related changes that occur from 65 to 100 years
of age were the main focus of this work. For a sound and
continuous description of an aging human, data on
anatomical and physiological changes ranging from early
adulthood to old age were included. The capability of the
PBPK approach to predict distribution and elimination of
drugs was verified using the test compounds morphine and
furosemide, administered intravenously. Both are cleared
by a single elimination pathway. PK parameters for the two
compounds in younger adults and elderly individuals were
obtained from the literature. Matching virtual popula-
tions—with regard to age, sex, anthropometric measures
and dosage—were generated. Profiles of plasma drug
concentrations over time, volume of distribution at steady
state (Vss) values and elimination half-life (t) values from
the literature were compared with those predicted by PBPK
simulations for both younger adults and the elderly.
Results For most organs, the age-dependent information
gathered in the extensive literature analysis was dense. In
contrast, with respect to blood flow, the literature study
produced only sparse data for several tissues, and in these
cases, linear regression was required to capture the entire
elderly age range. On the basis of age-informed physiol-
ogy, the predicted PK profiles described age-associated
trends well. The root mean squared prediction error for the
prediction of plasma concentrations of furosemide and
morphine in the elderly were improved by 32 and 49 %,
respectively, by use of age-informed physiology. The
majority of the individual Vss and t values for the two
model compounds, furosemide and morphine, were well
predicted in the elderly population, except for long fur-
osemide half-lifes.
Conclusion The results of this study support the feasibility
of using a knowledge-driven PBPK aging model that
includes the elderly to predict PK alterations throughout
the entire course of aging, and thus to optimize drug
therapy in elderly individuals. These results indicate that
pharmacotherapy and safety-related control of geriatric
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drug therapy regimens may be greatly facilitated by the
information gained from PBPK predictions.
Key Points
The course of healthy aging can be accounted for in a
physiologically based pharmacokinetic (PBPK)
model. The age dependence of distribution and
elimination processes is described by literature-
informed re-parameterization of organ volumes and
blood flow rates.
A knowledge-driven whole-body PBPK model is a
valuable tool for assessment of drug exposure in the
elderly, facilitating optimization of dosing regimens
and clinical trials with regard to the safety and
efficacy profile of a given compound.
1 Introduction
In developed countries, the elderly population is growing
rapidly. In the USA, the group of elderly above the age
of 65 years is expected to double by 2040 [1]. Globally,
the elderly population will exceed the number of chil-
dren by that decade [2]. This is due not only to a
decrease in birth rates but also to medical advances and
global prosperity, which have resulted in an increase in
life expectancy.
Elderly people receive the majority of drug prescrip-
tions. In the UK, the elderly account for only one fifth of
the population, yet they receive nearly 60 % of the pre-
scribed drugs [3]. This population is more likely to expe-
rience adverse drug events, because of polymedication and
differences in physiology between this age group and the
younger adults who are typically recruited in clinical trials.
Therefore, pharmacokinetic (PK) and pharmacodynamic
(PD) in elderly patients are difficult to estimate [4–6].
Although this vulnerable patient group should receive more
attention in clinical trials, this is difficult to realize, because
of morbidity and frailty [7]. Alternative approaches to the
conduct of clinical PK/PD studies in the elderly have to be
considered to obtain the required information for proper
dosing in the elderly. These approaches should incorporate
understanding of the course of human aging and the ability
to distinguish between age- and disease-related physio-
logical alterations.
The power and applicability of physiologically based
pharmacokinetic (PBPK) models have stimulated the
demand for a PBPK model tailored to the elderly [8, 9].
Moreover, the value of successful PBPK modelling
approaches in children [10, 11], pregnant women [12, 13]
and diseased subjects [14, 15], in order to investigate and
translate knowledge to special populations, has been rec-
ognized by regulatory authorities [16, 17]. This would
improve pharmacotherapy and increase the safety of
medications, thereby reducing costs resulting from adverse
events caused by suboptimal medication. A number of
PBPK models have already implemented parameters for
aging, but all of these have been highly focused on special
aspects such as enzyme activities [18] or volumetric
changes in single organs and overall blood flow [19]. An
overall understanding of the course of human aging and the
ability to distinguish between age- and disease-related
physiological alterations require a whole-body PBPK
approach. Therefore, establishing realistic models will
require incorporation of detailed descriptions of the age
dependence of anatomical and (patho)physiological
parameters. The aim of this study was to develop a whole-
body PBPK approach to understand and correctly predict
exposure to drugs in healthy, elderly Europeans between 65
and 100 years of age.
2 Methods
2.1 Collection of Data on Anthropometric,
Anatomical and (Patho)physiological Changes
with Age
The previously established database of Thompson
et al. [20] provided a sound basis for establishing a PBPK
model for the elderly age range but needed extension. Clear
data on sex, race and disease diversification, as well as
details regarding covariates, are pivotal for establishing
predictive PBPK models. Body weight and height or body
mass index (anthropometric measures), as well as
anatomical and (patho)physiological parameters, were
searched for in PubMed, using the filters ‘species-human’
and ‘ages-aged: 65? years’. Additional terms such as
‘age’, ‘ag(e)ing’, ‘elderly’ and ‘old’ were added for
refinement where needed. For parameters that yielded only
sparse literature in this initial search, an additional screen
was performed in Google Scholar and MedPilot. The
inclusion criteria were (1) clear assignment of sex;
(2) clear assignment of race; (3) a comprehensible state-
ment of the method of analysis; and (4) ruling out of
effects of medication or disease on subject physiology.
Studies that included longitudinal surveillance were pre-
ferred. Since in vivo measurements of organ size are not
directly comparable to measurements obtained from
autopsy reports, the former were taken into consideration
only for evaluation of muscle, fat and blood flow [21].
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Furthermore, for each study cohort, the available details
about body composition—for example, fat mass (FM), fat-
free mass (FFM) and lean body mass (LBM), as well as
total body water (TBW)—were extracted and used as
covariates. A second literature screen was performed for
the aging that occurs between 30 and 65 years of age
(younger adults), in order to refine the existing physio-
logical information and, thus, ensure that the data on aging
were continuous for the purpose of modelling.
In total, 19 studies from the database of Thompson
et al. [20] were used. Together with the second literature
search, 97 additional studies were added to build the aging
PBPK model.
2.2 Workflow for Elderly PBPK Model
Development
The workflow for this study is described in Fig. 1. Since
biological and chronological aging differ, the data were
analysed in 10-year age bins, as recommended by the
World Health Organization (WHO) [22], and interpolated
linearly. Thus, the data were pooled into seven age bins
covering the age range of 30–100 years, using Matlab, in
order to derive the distinctive age-related body composi-
tion across the lifespan throughout the European data set.
In cases where the pooling did not lead to an accept-
able description of the organ aging process, because of
insufficient data, additional data from North American and
Australian subjects were included.
Body composition for the same age may also vary
between different historical time periods because of vari-
ations in anthropometric measures or potential impacts of
national nutrition [23]. In order to cope with these secular
trends in study data published over the course of several
decades, a reference anthropometric measure for the age
range of the aging model that was considered was gener-
ated for each 10-year time period over the past 60 years. It
was applied whenever study data were stated without the
corresponding subjects’ anthropometric measures, to nor-
malize organ weights for the scaling approach based on
Willmann et al. [24].
The reported organ volumes originated mostly from
autopsy studies and thus represented cellular mass. They
were used mainly in determining respective organ volumes,
specific vascular fractions, interstitial fractions and
cytosolic proteins [10].
For each age bin, the processed organ masses were
summed up and found to reach 91–95 % of body weight;
the gap accounts for smaller organs not captured in this
model—for example, the adrenal glands, thyroid, tongue
and prostate. In order to reach the final body weights,
muscle and FM were increased in proportion to this gap.
Age-related changes in blood flow distribution were
accounted for as changes in cardiac output (CO). Blood
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flow rates and CO values were taken from the literature.
The sum of all blood flows should be equal to CO. Thus,
unknown age-dependent blood flows were scaled with
regard to their relative CO contributions in adults, as
postulated by the International Commission on Radiologi-
cal Protection (ICRP) report [25] to match age-related
changes in CO.
A virtual 30-year-old individual was created using the
PBPK software tool PK-Sim (version 5.5) [24]. On the
basis of this individual, a virtual population (N = 5000) for
each sex was generated by only predefining the desired age
range from 30 to 100 years. This population was used for
checks of physiological consistency. Body water distribu-
tion and single, simulated sizes of each organ by the newly
age-informed virtual population were compared with
unused data sets or nomograms.
2.3 Predictive Performance
In order to assess the predictive ability of the knowledge-
driven PBPK aging approach, two compounds with dif-
ferent major elimination pathways were selected: the high-
extraction drug morphine, which is up to 90 % cleared by
hepatic metabolism, and furosemide, which is cleared
mainly by the kidney. Model-building parameters are listed
in Table 1. The literature was screened for observed
plasma concentration–time profiles and corresponding PK
parameters in healthy European volunteers ranging from
young adults to the extremely elderly. Group data were
preferred, but whenever individual data with a description
of the subject’s anthropometric measures were provided,
corresponding virtual individuals were created. In cases of
missing anthropometric information, age-respective mean
values were used. Reported intrinsic clearance values were
used for the young adult simulation. The predictability of
the age-related impact on PK was then assessed in three
steps. First, simulated plasma concentration–time profiles
in the elderly were compared with observed profiles. In the
second step, age-related changes in elimination were
evaluated from shifts in elimination half-life (t) values.
Finally, altered body composition and changes in the
relationship between TBW and FM were assessed by cal-
culation of the volume of distribution at steady state (Vss),
with a non-compartmental analysis being performed. Two-
sided 1.25-fold and 2-fold levels of prediction accuracy for
the ratios of predicted to observed values of Vss, t and
plasma concentrations were applied for each compound.
2.3.1 Morphine
Morphine is a strong opioid analgesic and is indicated for
cancer pain. Because of its basic alkaloid structure, mor-
phine has low lipid solubility. It is metabolized by several
pathways leading to dihydromorphinone and normorphine.
Morphine binds to plasma proteins independently of its
concentration and is distributed to albumin, globulin and
glycoproteins. The drug has a high hepatic extraction ratio,
which is not affected by the dose [32]. In the PBPK model,
metabolism of morphine was implemented as an intrinsic
hepatic elimination process and thus affected only by age-
dependent changes in hepatic blood flow and tissue size.








Molecular weight, g/mol 330.74 285.30
LogP 1.75b 0.89 [26]
pKa 4.25 (acidic)b 7.90 (basic)b
Fraction unbound 0.03 [27] 0.80 [28]
Distribution
Partition coefficient model Willmann et al.c [29, 30] Willmann et al.c [29, 30]
Cellular permeability model Willmann et al.c [29, 30] Willmann et al.c [29, 30]
Metabolism/elimination
Elimination pathways
GFR fractiona 1 1
Renal clearance, mL/min/kg 1.61 [31]
Hepatic clearance, mL/min/kg 0.77 [31] 19.10 [28]
GFR glomerular filtration rate, LogP octanol–water partition coefficient, pKa acid dissociation constant
(on a log scale)
a Fraction of GFR used for passive renal elimination
b Information obtained from Drugbank (http://www.drugbank.ca)
c Willmann et al. [29, 30] is defined as the PK-Sim standard
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2.3.2 Furosemide
The loop diuretic agent furosemide induces production of
urine from water and sodium. It is moderately lipophilic
and undergoes only minor metabolism in the liver, which is
incorporated into the PBPK model as an non-specific
intrinsic process. As furosemide is highly bound to albu-
min, renal elimination is driven mainly by tubular secre-
tion, which delivers the compound to its site of action.
Although clearance is transporter driven, the magnitude is
accepted to be dose linear for the therapeutic range [33].
Thus, tubular secretion was implemented as an intrinsic
process in addition to passive filtration. Changes in kidney
tissue and the vasculature are known to alter renal elimi-
nation of furosemide and thus delivery to the target located
at the luminal side of the sodium–potassium–chloride
cotransporter in the loop of Henle [34].
2.3.3 Statistical Analysis
After the PBPK model was built using observed adult data,
studies in the elderly were simulated by creating virtual
individuals matching anthropometric measures of the
clinical study populations or individuals. Virtual individ-
uals were generated by two means: with use of either the
physiology of a young adult as an uninformed simulation,
or with use of physiological information for the elderly
gathered within this study as an age-informed simulation.
The precision of simulated PK parameters was evaluated
with the root mean squared prediction error (RMSE) and
the bias based on the mean prediction error (ME), using
weighted residuals. In order to estimate the improvement
with application of age-informed physiology for predic-
tions in the elderly data set, a relative bias was calculated
by subtraction of the informed from the uniformed pre-
dictions (DME). The same procedure was used to calculate
the precision (DRMSE). The changes were also set in
relation to the uninformed predictions and expressed as
percentages.
3 Results
In the main part of this paper, the physiology dominating
the PK in the model—including hepatic and renal changes,
as well as the redistribution of fat and muscle mass—are
reviewed. Also, cardiovascular and body water distribution
are highlighted. A description of the physiology of less
dominant organs within the whole-body aging PBPK
approach is given in the Electronic Supplementary Mate-
rial, including a summary of the literature used. The overall
body composition over the course of aging, as implemented
in the elderly PBPK approach, is listed in Table 2 and
visualized in Fig. 2. The age-dependent volumetric devel-
opment of all organs is described in detail in the Electronic
Supplementary Material.
3.1 Physiological Changes in the Elderly
3.1.1 Anthropometric Measures
Anthropometric measures were stated in almost every
physiological study. In addition, comprehensive European
anthropometric studies [35–46] were used, and coverage
was dense for the age range of 30–100 years.
In general, men tended to be taller and heavier than
women at any age stage. Both sexes showed an increase in
body mass up to the age of 55 years, and then a progressive
decrease. This decline started as a 1.5 % decrease per
decade and rose to nearly 10 % per decade between 90 and
100 years of age. Body height started to decrease in early
adulthood, after the age of 30 years, as visualized in Fig. 3.
As with body weight, the decrease started with a low rate
of 1 % per decade and was comparable for men and
women. In women, this rate accelerated after menopause,
culminating in a 4.2 % decrease in body height per decade
in female nonagenarians. In males, height loss during the
tenth decade averaged only about 3.5 %.
3.1.2 Muscle Mass
Loss of muscle mass is assessed as part of the screening
test for sarcopenia, using the gold standard methods com-
puter tomography (CT) and magnetic resonance imaging
(MRI) [47], but also using dual-energy X-ray absorptiom-
etry (DXA) [48–52] or bioimpedance analysis (BIA)
[53–58], according to the European Working Group on
Sarcopenia [59]. Janssen et al. [60] introduced an equation
enabling calculation of skeletal muscle mass from BIA
observations. As decreases in muscle mass vary between
different parts of the body, whole-body analysis was pre-
ferred for the data pooling. The degressive decline in the
maximum skeletal muscle mass from 37 % of body weight
in adults to 22 % in the centenarian female opposed the
progressive reduction from 44 % of body weight in adults
to 34 % in extremely old males.
3.1.3 Fat Mass
Like muscle mass, FM can generally be assessed using CT
[61], MRI, BIA [43, 53, 62–66] or DXA [41, 67–79].
Estimations based on skinfold thickness and whole-body
count for total potassium content were not included,
because of the varying methods of calculation [80].
During aging, FM in females increased to an absolute
maximum at the age of 70 years, whereas in males, this
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peaked by the age of 65 years. Because of the diminished
body weight and the severe loss of LBM from 70 to 100
years of life, the relative FM continued to increase, to as
much as 45.8 % in female and 31.5 % in male centenari-
ans. Here, the increases were constant in males, with 0.978
kg FM/decade. Females, however, experienced an accel-
erated gain of 3.50 kg FM/decade in the first two decades
after menopause, and then a reduction to the same rate as in
males of the same age group.
3.1.4 Kidney Weight
Four studies were included for model building [81–84].
These revealed that maximum kidney weight was achieved
in the fourth decade and remained constant for almost 20
years before continuously declining. This decrease was
associated with loss of renal tissue and a reduction in the
number of nephrons, particularly in the renal cortex [85].
This resulted in a reduction in tubular and glomerular cells,
Table 2 Anthropometric measures, organ weights and tissue weights, including blood content, as used in the elderly physiologically based
pharmacokinetic (PBPK) models
Parameter Sex Age, years
30c 40 50 60 70 80 90 100
Body weight, kg Female 60.0 63.3 65.2 65.5 62.2 56.1 53.7 45.2
Male 73.0 74.4 73.0 72.0 71.1 68.1 64.9 55.6
Height, cm Female 163.0 160.9 160.0 158.3 155.4 151.7 150.0 147.9
Male 176.0 175.1 173.9 171.2 167.4 165.5 163.8 157.6
Organ masses, ga
Blood poolsb Female 1899.4 1921.1 1961.2 1946.9 1847.7 1692.6 1634.5 1357.0
Male 2264.6 2269.5 2234.9 2180.2 2111.3 2042.5 1976.5 1739.5
Bone Female 9121.5 8886.3 8676.1 8401.8 7811.6 6981.4 6619.0 6263.5
Male 11,817.8 11,848.0 11,481.6 11,091.6 10,355.0 9637.1 8969.0 8300.9
Brain Female 1357.0 1352.3 1347.6 1315.1 1287.3 1241.4 1169.4 1097.4
Male 1508.8 1506.9 1502.9 1463.3 1434.3 1400.1 1372.1 1344.2
Fat Female 19,348.0 20,002.5 23,815.4 26,993.0 27,884.7 25,694.5 25,020.6 20,171.4
Male 14,868.0 16,309.7 16,676.5 17,920.7 19,447.4 19,947.7 20,691.0 17,082.3
Gonads Female 13.1 13.0 6.6 5.3 5.2 5.1 5.1 4.9
Male 40.3 40.8 35.0 33.5 31.9 30.6 30.3 29.5
Heart Female 328.4 340.0 355.6 377.1 399.1 413.5 431.2 412.9
Male 417.2 434.3 439.1 454.6 464.8 441.4 437.9 425.1
Kidney Female 403.4 401.7 400.5 383.4 364.2 325.2 308.8 295.8
Male 437.7 475.9 468.1 455.6 441.7 395.7 366.7 355.9
Liver Female 1905.5 1881.0 1867.7 1679.8 1504.9 1423.4 1329.5 1189.4
Male 2357.8 2324.5 2206.0 2041.3 1714.6 1417.3 1324.0 1202.0
Lung Female 1009.5 1021.4 1038.8 1023.8 1005.4 849.1 804.5 637.3
Male 1294.3 1334.7 1337.4 1349.0 1271.8 1138.0 1007.4 978.0
Muscle Female 20,276.2 23,058.3 21,300.1 18,971.2 15,746.4 13,367.8 12,394.3 10,060.6
Male 32,338.6 32,318.2 31,180.6 29,600.0 28,562.1 26,524.8 23,657.0 19,534.0
Pancreas Female 169.5 170.3 163.8 158.7 148.5 131.9 128.0 122.6
Male 190.3 190.8 183.6 178.2 165.4 149.9 143.7 139.5
Skin Female 2723.5 2773.2 2836.2 2829.5 2725.8 2559.1 2493.8 2223.5
Male 3760.9 3790.2 3745.1 3692.0 3635.2 3537.0 3439.7 3122.6
Spleen Female 219.2 197.7 190.7 182.4 164.5 149.7 99.4 78.7
Male 243.4 221.9 208.2 197.0 186.6 160.4 133.4 108.4
a Organ masses for gastrointestinal organs were kept constant for females (1274.5 g) and males (1304.8 g) over the investigated age range
b Blood pools represent arterial and venous blood, as well as blood in the portal vein
c Physiological and anatomical information on the 30-year-old individuals is derived from the International Commission on Radiological
Protection reference man [25]
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and thus affected the glomerular filtration rate (GFR)
[86, 87].
3.1.5 Liver Weight
The number of hepatocytes was reduced in the elderly,
whereas the single-cell volume initially increased but
subsequently decreased [88]. Thus, the number of hepatic
lobules was constant over the course of aging, but the size
of the liver declined, while collagen accumulation induced
a widening of the perisinusoidal space [89]. In females,
liver mass decreased almost linearly at the rate of 8.3 %
per decade after the age of 40 years, whereas in males, it
proceeded in two steps: an initial decline of 6.1 % per
decade to the age of 60 years, followed by a more rapid
loss of 11.4 % per decade [82–84, 90, 91]. This tendency
was determined from autopsy analysis but was also
detected in imaging studies [92–94].
3.1.6 Cardiac Output Distribution
Williams [95] conducted a comprehensive literature anal-
ysis on changes over the course of aging in CO and the
cardiac index, a parameter that relates CO to body surface
area (BSA). His study revealed that an initial decrease in
cardiac index after the age of 20 years developed into a
marked reduction after the sixth decade of life. Given that
Williams summarized predominantly North American
reports and a large Japanese trial, European studies were
screened to control for potential racial variations. The
studies taken into account for evaluating both changes in
CO [96–99] over the course of aging and the underlying
distributions are listed in Supplementary Table 1.
Females showed an almost linear decrease in cardiac
index of 3.22 % per decade after the age of 30 years. The
slowing of the cardiac blood circulation was more precip-
itous in males, where it started at 1.46 % per decade during
Fig. 2 Distributions of mean
organ weights in females (left)
and males (right), from
newborns to individuals up to
100 years of age.
GI gastrointestinal
Fig. 3 Age-dependent changes in body height: comparison between
simulations (grey dots) [N = 5000] and observations (reference mean
data; black circles) in females and males. The reference data were all
gathered from anthropometric studies or studies where they appeared
as covariates. The sizes of the black circles indicate the relative
numbers of subjects
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early adulthood, followed by a stronger decrease of 8.30 %
per decade in the elderly age range. These results were
confirmed by studies on stroke volume [100–102],
assuming that the heart rate remained constant over the
lifespan. However, because of contradictory reports on
changes in heart rate over the course of aging (some reports
supported a decrease in heart rate, due to the dropout of
pacemaker cells [103, 104] whereas others indicated that
the heart rate increased in female subjects [105]), reports
on isolated stroke volumes were not taken into account.
3.1.7 Kidney Blood Flow
In the kidney, the age-dependent decrease in the absolute
perfusion rate was more severe than the weight loss. In
comparison with the perfusion rate, the overall reduction in
CO proceeded at a slower rate. Correlation of kidney
perfusion and filtration performance was shown in a larger
population ranging from 20 to nearly 90 years of age [106].
Para-aminohippuric acid (PAH) is the marker substance of
choice for the assessment of renal blood flow; in the past, it
was diodrast [107–109].
3.1.8 Hepatic and Splanchnic Blood Flow
In healthy adults, the pre-portal organs, including the
stomach, intestines, pancreas and spleen, provided about
75 % of the portal blood flow [10]. This relationship
seemed to be maintained over the course of aging, although
the total flow rate decreased [110]. Additional shunting was
negligible when the blood flow rate was reduced and portal
pressure remained constant. The hepatic blood flow itself
was measured using the dye dilution method, where a
subject was catheterized in the portal and hepatic veins
[93]. In order to eliminate potential anastomosis, additional
studies based on Doppler measurements were integrated
into this analysis.
Although no absolute information was obtainable for
splanchnic blood flow, relative alterations could be
analysed by laser Doppler flowmetry. Analysis of the
blood flow in the superior mesenteric artery was the
most common assessment of alterations in splanchnic
perfusion [111–113]. Although the superior mesenteric
artery is one of three vessels that contribute to the
splanchnic blood supply, it is the major sustenance
vessel of the small intestine, the duodenum and the
colon. Alterations in perfusion of the stomach, pancreas
and spleen could also be captured by this method. The
ratio of splanchnic blood flow to CO gradually decreased
from 22.5 % in adults to 17.5 % during the tenth decade
of life [114–117].
In summary, information on blood flow alterations
implemented in the elderly PBPK approach is listed in
Table 3. The general lack of perfusion data impeded
computation of robust variability for each blood flow rate,
and so a 5 % coefficient of variation was assumed as
accepted for other approaches [19].
3.1.9 Total Body Water Distribution
TBW remained stable throughout most of adulthood but
decreased starting in the sixth decade of life. Race and sex
have been associated with differences observed over the
complete lifespan [118]. Normalization of TBW to body
weight revealed that the ratio declined gradually during the
aging process. This reduction was mainly due to loss of
intracellular water; the ratio of extracellular water to body
weight was maintained during aging. These changes are
visualized in Fig. 4, together with observed data in healthy
Caucasians [43, 64, 119–122].
3.1.10 Glomerular Filtration Rate
In order to generate population samples large enough to
investigate the GFR, most studies were carried out in
prospective renal transplant donors, using exogenous
markers [123–126]. An analysis of the gathered and BSA-
adjusted data for 1213 females and 1081 males was per-
formed. This resulted in a slight reduction starting at the
age of 30 years and a more rapid reduction starting at the
age of 40 years.
The GFR in PK-Sim is linked to maturation of the
kidney volume and is described by a Hill function [127].
To describe the effect of aging on the GFR, a new, reverse
sigmoid hyperbolic maturation function was developed and
optimized with the Matlab function lsqnonlin, starting
(for both sexes) at the age of 30 years.
Specific GFR30100y ¼ FPMA  1 Vmax  age 30 yearsð Þ
Hill
TAHill50 þ age 30 yearsð ÞHill
 !
ð1Þ
Here, FPMA is the specific GFR derived from the
sigmoid hyperbolic maturation function [127] after full
maturation is achieved in the 40th week of gestation (26.6
mL/min/100 g kidney weight) [128]. In order to describe
the effects of aging on kidney function, the maximal
decreasing rate factor (Vmax) was 0.9 mL/min/100 g kidney
weight, and the aging half-time (TA50) was 59 years for
females and 54 years for males. The Hill coefficient was
parameterized at 1.5. The resulting function over the aging
period is visualized in Fig. 5. While specific GFR function
was parameterized using the observed GFR values and
assuming the mean kidney weight at the respective age, the
variability was entirely dependent on the deviation in
kidney weight.
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3.2 Predictability of PK Data in the Elderly
The literature screen for observed PK data led to inclusion
of several studies of morphine [129–136] and furosemide
[31, 137–140], as listed in Table 4. The simulated plasma
concentration–time profiles of furosemide and morphine in
healthy adults were consistent with the observed data, as
visualized in Fig. 6. The scaling to older ages reported in
the above-mentioned drug studies led to an accurate
description of the estimated PK parameters, as shown in
Figs. 7 and 8.
Table 3 Cardiac index and organ blood flow rates used in the elderly physiologically based pharmacokinetic (PBPK) models
Parameter Sex Age, years
30b 40 50 60 70 80 90 100
Cardiac index, L/m2 Female 3.34 3.33 3.08 2.89 2.75 2.68 2.52 2.41
Male 3.23 3.22 3.09 2.86 2.58 2.36 2.18 2.04
Organ blood flow, mL/min
Adipose Female 501.1 528.2 578.0 655.3 684.7 630.2 607.0 491.5
Male 324.7 352.1 357.3 381.4 408.0 419.8 429.2 357.3
Cerebral Female 707.8 686.9 666.1 632.1 601.2 562.8 514.2 467.6
Male 779.7 747.6 727.9 692.9 650.6 623.8 594.4 536.1
Gonads Female 1.2 1.2 0.6 0.5 0.5 0.5 0.5 0.4
Male 3.2 3.3 2.8 2.7 2.6 2.5 2.4 2.4
Myocardial Female 295.0 311.2 313.2 363.1 376.3 445.8 464.8 445.2
Male 260.1 271.1 278.0 299.1 308.7 334.7 332.1 322.3
Renal Female 1121.0 1061.8 943.8 825.8 707.8 589.8 471.8 353.8
Male 1325.0 1339.3 1116.3 913.3 730.3 567.3 424.3 301.3
Splanchnica Female 1239.0 1254.3 1187.2 1015.3 862.6 771.5 679.1 570.5
Male 1235.0 1241.9 1237.7 1056.7 813.1 610.6 512.9 413.5
Hepatic Female 383.4 388.1 367.3 314.2 266.9 238.7 210.1 176.5
Male 423.0 425.4 423.9 361.9 278.5 209.1 175.7 141.6
Muscle Female 665.1 774.8 636.6 568.4 479.8 405.6 369.0 298.8
Male 1105.7 1086.8 1036.8 975.0 922.3 861.7 751.9 625.9
Skeleton Female 294.9 287.3 280.5 271.6 252.6 225.7 214.0 202.5
Male 324.9 325.8 315.7 305.0 284.7 265.0 246.6 228.2
Skin Female 295.7 301.1 307.9 307.2 295.9 277.8 270.7 241.4
Male 325.1 327.7 323.8 319.2 314.3 305.8 297.4 270.0
a The splanchnic blood flow rate combines gastrointestinal, pancreatic and splenic blood flow, and describes portal blood flow
b Cardiac output distribution information on 30-year-old individuals is derived from the International Commission on Radiological Protection
reference man [25]
Fig. 4 Distribution of body
water in males (left) and females
(right) over the course of aging.
Extracellular body water (dark
grey lines) and total body water
(light grey lines) are shown as
percentages of body weight.
Values reported in the literature
for extracellular water
(triangles) and total body water
(circles) are shown for
comparison
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The predictive performance of the PBPK models of
furosemide and morphine is summarized in Table 5. The
precision of the predictions of plasma concentrations
improved by 0.132 and 0.212 for furosemide and mor-
phine, respectively, with use of age-informed physiology
for the simulations of the elderly studies. This represented
relative improvements in the predictions, by 32 % in the
case of furosemide and by 49 % in the case of morphine.
For both drugs, the plasma concentrations were underpre-
dicted in the absence of consideration of age-informed
physiology. The bias was considerably reduced when age-
informed physiology was applied.
The scaling to older ages reported in the above-men-
tioned drug studies led to an accurate description of the
estimated PK parameters, as shown in Figs. 7 and 8. All
but four of 36 predicted Vss values for furosemide were
within 1.25-fold of the experimental values. The predicted
t of furosemide in individuals with a longer half-life was
underpredicted. Here, eight of 36 values of t were not
within the 1.25-fold range. Reliable predictions were
obtained for the Vss and t of morphine. Only three indi-
vidual values for Vss and two of eight individual values for
t were outside the 1.25-fold range without any age-related
pattern.
Fig. 5 Changes in kidney function in females (left) and males (right)
over the course of aging. To describe the influence of aging on the
glomerular filtration rate (GFR), a new reverse sigmoid hyperbolic
maturation function was developed and applied to both sexes, starting
at the age of 30 years. Changes in the GFR were investigated by
analysis of exogenous markers in prospective renal transplant donors.
A stepwise regression analysis of the gathered data, normalized to
body surface area (BSA), was performed for 1213 females (upper
panel) and 1081 males (lower panel). A solid black line represents the
new GFR function in relation to kidney weight, and a dashed black
line represents the maturation of GFR function according to Rhodin
et al. [127]. The grey shaded areas represent the predicted 95 %
percentile range based on kidney size variability. The black circles
depict the observed GFR rates [123–126]
Table 4 Summary of clinical
studies after intravenous dosing
of the test compounds used to
compare the simulated data
Dose Age, years N Height, cm Weight, kg References
Morphine
0.125 mg/kg 30.6 (24–40) 11 62.6 (47–85) [129]
10 mg 27.4 (26–30) 8 67.6 ± 4.5 [130]
74.0 (68–90) 9 66.4 ± 3.2
5 mg 31 (26–40) 6 [131]
5 mg 30.2 (25–44) 10 72 (63–83) [132]
5 mg 25.8 (20–40) 6 71.4 (49.2–102.1) [133]
0.05 mg/kg 76.1 ± 4.5 16 167.4 ± 8.3 77.8 ± 16.9 [134]
10 mg (22–29) 12 76.4 ± 7.4 [135]
10 mg (20–39) 14 74.9 ± 11.0 [136]
Furosemide
80 mg 27.1 (20–35) 10 71.4 ± 6.7 [31]
80 mg 27 ± 4.8 8 71 ± 6.7 [137]
64 ± 4.0 8 76 ± 7.3
40 mg 30 (20–45) 7 [138]
20 mg 76 1 70 [139]
40 mg 74 (64–84) 20 73.1 ± 12.8 [140]
Values are expressed with ranges (in parentheses) or ± standard deviations
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Fig. 6 Upper panel: predicted mean plasma concentration–time
profiles of furosemide and morphine in younger adults (grey dashed
line) versus the elderly (black line). The concentrations are normal-
ized to a 40 mg dose for furosemide and to a 10 mg dose for
morphine. Observed data are superimposed (black open symbols
represent values for the elderly [130, 134, 137]; grey open symbols
represent values for younger adults [129, 130, 133,
136–138, 141, 142]). Lower panel: goodness-of-fit plots for
furosemide and morphine model predictions in the adult population
(black dots) and the elderly population (grey dots). A solid line
represents the line of identity; dashed lines represent the 1.25-fold
error range and dotted lines represent the 2-fold error range
Fig. 7 Observed versus
predicted values for the volume
of distribution at steady state
(Vss) and elimination half-life
(t), as well as the
corresponding fold over-/
underprediction, for the test
compound furosemide. A solid
line represents the line of unity;
dashed black lines represent the
1.25-fold level and grey lines
represent the 2-fold level of the
predicted accuracy
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4 Discussion
The PBPK aging approach described here summarizes
anatomical and (patho)physiological changes from early
adulthood to extreme old age. Data were extracted from the
peer-reviewed literature for all relevant PBPK parameters
and analysed in order to describe the systemic changes that
occur with age.
Only a few studies have attempted geriatric PBPK
modelling by including aging considerations in their data-
bases. The recent approach by McNally et al. [19] included
detailed considerations of age-related changes in brain
weight and bone mass. Also, the implementation of muscle
mass alterations according to Janssen et al. [47], as well as
the analysis of changes in CO by Luisada et al. [143], have
proven to be useful for PBPK modelling for the elderly. By
informing bone and muscle mass, this approach considers
changes in FM indirectly. However, alterations in CO
distribution and changes in major organs (such as the liver
and kidney) were not captured by data from the literature
[19, 143].
The gathering of data from the literature for PBPK
application is a serious challenge. Some organs, such as the
brain, have been well described over the entire age range,
Fig. 8 Observed versus
predicted values for the volume
of distribution at steady state
(Vss) and elimination half-life
(t), as well as the
corresponding fold over-/
underprediction, for the test
compound morphine. A solid
line represents the line of unity;
dashed black lines represent the
1.25-fold level and grey lines
represent the 2-fold level of the
predicted accuracy








































32 % 49 %
Values are expressed in mg/L with 95 % confidence intervals (in parentheses)
ME mean prediction error, RMSE root mean squared prediction error, DRMSE difference in RMSE
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because of advances in analytical methods and enhanced
focus on research in these areas. This has enabled inves-
tigations into secular trends and tracking of longitudinal
aging trends. For other organs, however, the available data
are sparse or outdated. One of the main cited studies
referring to changes in liver weight over the course of
aging was performed by Boyd [144], dating from 1933; this
study included severely diseased individuals. Generally,
because of the higher survival rate of women, data yield for
extreme old age was less representative for men. Another
hurdle is the research on massive blood-containing organs
such as the lung and the spleen. Here, an infection prior to
death can cause great variability in the reported weight at
autopsy. Furthermore, in contrast to gestation and matu-
ration, which involve highly predictable biological changes
over a defined time scale, classification of individuals
beyond the age of 65 years has no physiological basis. This
impedes generation of a clear reference interval for a cer-
tain chronological sequence and thus increases variability.
In contrast to studies on changes in organ volume during
the aging process, studies on blood flow rates and CO
distribution have been sparse or used questionable analyt-
ical methods. In these cases, our data collection included
information from studies in North Americans and Aus-
tralians, and linear regression was performed. Since no
study covered the topic of gonadal perfusion, specific blood
flow was kept constant and only volumetric change in these
organs was taken into account. Moreover, the last data
point for muscle blood flow was for a group of 73-year-old
subjects, allowing only a linear regression from young
adulthood up to 100 years of age. Similarly, no studies on
body water distribution were available for females above
the age of 80 years. Besides lack of data, the predicted
variability in the GFR based on kidney size variability was
too great throughout the course of aging, as can be seen in
Fig. 5. Alternative approaches, such as correlation of GFR
and renal plasma flow, have been proposed by others [106]
because of the uncertain extent of glomerulosclerosis. The
postulated blood flow rate variability would propagate to
the GFR calculation to yield a narrower variability distri-
bution in comparison with propagation of kidney size
variability.
In the current study, parameters relevant to a PBPK
approach were gathered by a comprehensive review of the
literature and, for the first time, they were integrated into a
knowledge-driven PBPK aging approach that captured
whole-body physiology. This methodology enabled an age-
dependent description of plasma concentration–time pro-
files for young adults and elderly (Fig. 6). Importantly, the
clinically observed increasing plasma concentrations of
both drugs in the elderly were reflected by the aging PBPK
model. Along with this, as shown in Figs. 7 and 8, this
approach allowed description of the shifts in Vss and t for
selected compounds. Unfortunately, only a few studies
providing plasma concentration–time profiles were avail-
able; thus, an age-grouped analysis was not feasible.
Especially for the age ranges of 40–60 years and 85–100
years, there were hardly any stratified PK data. When the
underlying physiological changes were used, the predic-
tions were reasonably precise over the entire age range.
There was an underprediction of higher t values for fur-
osemide, which could have been due to temporary
decreases in the kidneys’ hydrodynamics observed in
several patients in the first 2–3 h after intravenous
administration [34]. This dose–response relationship is
considered to be dose dependent [145] and could be
assessed with an additional PD model. Variability in
morphine PK is associated with variation in protein con-
centrations. Perturbed levels of albumin and acidic glyco-
protein may occur in patients suffering from acute or
chronic pain, as a result of immobility. This, in turn, would
strongly impact the extent of morphine binding to plasma
proteins [28]. Because of the high extraction ratio, age-
related changes in the vasculature and hepatic tissue are
more descriptive of the fate of morphine [28, 146].
This paper supports specific considerations for the aged
population in geriatric clinical trial designs, as this group
receives the greatest number of drug prescriptions. The
established PBPK aging approach represents a valuable
tool for age-related PBPK modelling. With this approach,
anatomical and (patho)physiological age dependence can
be used to predict alterations in PK from early adulthood
through extreme old age. This will improve prediction of
effective starting drug dosages for healthy elderly patients,
as depicted in Fig. 1 and emphasized by Jadhav et al.
[147]. Further disease implementations are encouraged in
order to distinguish between age- and/or disease-related
physiological alterations in drug usage. In general, this
knowledge-driven approach is expected to be effective for
increasing the efficiency of clinical trial designs, as well as
for optimizing drug therapy in the elderly population.
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